Bone growth stimulators are tools that promote healing and recovery of bones during treatment of delayed unions, fresh fractures, failed spinal fusions, and fracture nonunion. They generate a series of ultrasonic waves or electrical impulses that create pressure on bone tissues. This pressure triggers cells responsible for bone formation to form and mineralize new bones through the process of remodeling.
External Bone Growth Stimulation Devices to Remain Preferred Choice of Patients
Bone growth stimulators are available in the form of bone morphogenetic proteins (BMP), bone growth stimulation devices, and platelet-rich plasma (PRP). Bone growth stimulation devices can be further classified into ultrasonic, external, and implanted. Among these, external devices represented the leading share in 2016. The dominance of the segment can be attributed to surging demand for noninvasive surgical treatments for bone healing. These devices are portable, lightweight, battery powered, and easy to handle, owing to which their popularity is rising among patients. In addition, they are less expensive than implanted devices, which in turn is stirring up their demand in developing countries such as India, China, and South Africa.
Approval of new and advanced external bone growth stimulation devices is also likely to augment the growth of the segment. For instance, in January 2017, Orthofix International N.V. received FDA approval and CE mark for its next-generation Spinal-Stim and Cervical-Stim bone growth stimulators. These systems were launched along with a mobile application called Stim onTrack.
Demand for PRP and BMP is anticipated to witness a sharp rise through 2025. Globally, PRP is acknowledged for its low side effects, zero risks of allergic reactions, and high safety. Growing occurrence of spinal injuries and arthritis is supplementing the growth of the segment.
Market Insights
The findings of a report by Grand View Research, Inc. indicate that the global bone growth stimulator market is projected to attain a size of USD 1.4 billion by the end of 2025. Rising prevalence of arthritis is one of the primary factors driving the market. Widening base of geriatrics and obese population is contributing to the increasing cases of arthritis. Aging individuals are the most prone to gouty arthritis and osteoarthritis. According to the Arthritis Foundation, the number of Americans suffering from arthritis is anticipated to reach 78.4 million by 2040.
North America led the market in 2016 in terms of revenue. Increasing incidence of vertebral fractures or osteoporosis in the region is translating into the greater uptake of bone growth stimulators. Some of the key companies operating in the market are Zimmer Biomet; Arthrex, Inc.; DJO Global, Inc.; Medtronic; and Bioventus LLC.
In-Depth research report on bone growth stimulator market, click the below link:
In-Depth research report on bone growth stimulator market, click the below link:
No comments:
Post a Comment